By generating the Pb-Cre+;PtenL/L;CD166−/− line, our study demonstrates that loss of CD166 within LSChi population does not change their ability to form spheres in vitro and block prostate cancer initiation and progression in vivo. Here, ALCAM is linked to prostate cancer.